About E3 SUMO-protein ligase EGR2
E3 SUMO-protein ligase EGR2 (EGR2) is a protein
from Homo sapiens identified by UniProt accession
P11161, 476 residues long.
MolForge cross-references it against 0 known binders and
423 disease associations.
Target properties
| Protein name | E3 SUMO-protein ligase EGR2 |
| UniProt accession | P11161 |
| Gene | EGR2 |
| Organism | Homo sapiens |
| Length | 476 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (423)
Diseases linked to this target (Open Targets).
- Charcot-Marie-Tooth disease type 1D · score 0.79
- Charcot-Marie-Tooth disease type 3 · score 0.69
- Dejerine-Sottas syndrome · score 0.69
- Charcot-Marie-Tooth disease type 4E · score 0.65
- Charcot-Marie-Tooth disease type 1 · score 0.54
- eosinophil count · score 0.49
- neurodegenerative disease · score 0.45
- lymphocyte count · score 0.42
- Charcot-Marie-Tooth disease · score 0.42
- eosinophil percentage of leukocytes · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11161-F1 | alphafold | PREDICTED | 47.84 | — |
Amino-acid sequence (476 residues)
MMTAKAVDKI PVTLSGFVHQ LSDNIYPVED LAATSVTIFP NAELGGPFDQ MNGVAGDGMI NIDMTGEKRS LDLPYPSSFA PVSAPRNQTF TYMGKFSIDP QYPGASCYPE GIINIVSAGI LQGVTSPAST TASSSVTSAS PNPLATGPLG VCTMSQTQPD LDHLYSPPPP PPPYSGCAGD LYQDPSAFLS AATTSTSSSL AYPPPPSYPS PKPATDPGLF PMIPDYPGFF PSQCQRDLHG TAGPDRKPFP CPLDTLRVPP PLTPLSTIRN FTLGGPSAGV TGPGASGGSE GPRLPGSSSA AAAAAAAAAY NPHHLPLRPI LRPRKYPNRP SKTPVHERPY PCPAEGCDRR FSRSDELTRH IRIHTGHKPF QCRICMRNFS RSDHLTTHIR THTGEKPFAC DYCGRKFARS DERKRHTKIH LRQKERKSSA PSASVPAPST ASCSGGVQPG GTLCSSNSSS LGGGPLAPCS SRTRTP
Explore E3 SUMO-protein ligase EGR2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets